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Summary
Recently, the European Society of Cardiology (ESC) and
the European Atherosclerosis Society (EAS) published a
consensus paper giving guidance on the definition and
management of statin-associated muscle symptoms
(SAMS), as well as the use of proprotein convertase sub-
tilisin kexin 9 (PCSK9) inhibitors in very high-risk pa-
tients. The occurrence of SAMS can have a major negative
impact on treatment adherence and, consequently, on the
prognosis of cardiovascular diseases. In addition, both the
ESC guidelines on the prevention of cardiovascular disease
(CVD) in clinical practice with sections addressing global
strategies to minimise the burden of CVD at population and
individual levels, and the 2016 ESC/EAS guideline for the
management of dyslipidaemias, focus on evaluation and
treatment of SAMS. The release of these guidelines was a
source of great interest to clinicians, as new emergent ther-
apies, such as the PCSK9 inhibitors, have been approved
for the treatment of dyslipidaemias: recently, both the US
Food and Drugs Administration (FDA) and the European
Medicines Agency (EMA) approved the use of PCSK9 in-
hibitors as add-ons for the treatment of hypercholestero-
laemia in cases where low-density lipoprotein cholesterol
(LDL-C) target levels could not be reached with maxim-
um tolerated statin doses alone, or instead of statins in
the event of SAMS. Because of the relatively high cost of
these new therapies, physicians need to justify the use of
PCSK9 inhibitors by demonstrating that their high-risk pa-
tients’ LDL-C levels have remained high (1) despite a well-
conducted, but insufficiently effective high-intensity statin
therapy (e.g. rosuvastatin 10–20 mg or atorvastatin 40–80
mg), or (2) in the event of the patient developing side ef-
fects, in particular severe SAMS, during treatment with at
least three statins. In addition to SAMS, the use of PCSK9
inhibitors may be considered in patients with documented
atherosclerotic cardiovascular disease or in patients with
familial hypercholesterolaemia and poorly controlled LDL-
C under the combination of maximum tolerated stain and
ezetimibe.
Key words: lipids; statin; PCSK9 inhibitors;
cardiovascular prevention
Introduction
Statins are one of the most widely prescribed medications
and the recommended first-line pharmacological therapy
for the treatment of hypercholesterolaemia [1]. Statin ther-
apy decreases low-density lipoprotein cholesterol (LDL-C)
levels by up to 50%, and, subsequently, the incidence of
cardiovascular events [2]. Large meta-analyses have shown
that for each 1 mmol/l decrease in LDL-C levels, the re-
lative risk of cardiovascular events is reduced by 20%,
but with a larger absolute risk reduction among high-risk
patients [3]. Therefore, guidelines recommend the use of
appropriate clinical scores to identify patients who could
most benefit from statin therapy, especially those at high
risk of cardiovascular events [2, 4]. Although statins
demonstrate long-term efficacy in reducing LDL-C levels,
some concerns still remain regarding their safety. Although
no significant differences in adverse event rates (including
muscle symptoms) have been highlighted between statin
and placebo arms in randomised controlled trials [5], in
real-life data sources, such as registries, between 7 and
29% of patients complain of SAMS [6–8]. These are usu-
ally benign with normal or slightly increased creatine
kinase (CK) concentrations; less than 1% (1 per 1000 to 1
per 10 000 per year) develop a serious adverse event in the
form of myositis and CK elevation >10× the upper limit of
normal (ULN) [9]. The advent of SAMS also depends on
statin dosage and the presence of other risk factors [10].
Recently, the European Society of Cardiology (ESC) and
European Atherosclerosis Society (EAS) published a con-
sensus paper giving guidance on the definition and man-
agement of SAMS [11]. In addition, both the ESC
guidelines on the prevention of cardiovascular disease
(CVD) in clinical practice with sections addressing global
strategies to minimise the burden of CVD at population and
individual levels [12], and the 2016 ESC/ EAS guideline
for the management of dyslipidaemias, focus on evaluation
and treatment of SAMS [13]. The release of these
guidelines was a source of great interest to clinicians, as
new emergent therapies, such as proprotein convertase sub-
tilisin kexin 9 (PCSK9) inhibitors, have been approved for
the treatment of dyslipidaemias [14]. The publication of
guidelines is especially important for clinicians faced with
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controversial situations, such as the use of statin therapy
in primary prevention, but they are also meant to help to
provide more consistent care based on available evidence.
Evidence on the management of lipid disorders is currently
developing fast after recent findings with nonstatin agents,
such as jejunal NPC1L1 protein blockers (ezetimibe) [15]
or the novel PCSK9 inhibitors [16]. Nonstatin agents may
come to play an increasingly important role as add-ons to
statins to further decrease LDL-C levels, or even as sub-
stitutes for statins in the case of statin intolerance [14].
This is especially true in secondary prevention after acute
coronary syndrome (ACS), where the recommended LDL-
C target is very stringent (≤1.8 mmol/l; ≤70 mg/dl), or in
patients with SAMS [17]. In the light of these new develop-
ments, this review aims to provide an update for clinicians
about the main issues surrounding SAMS and their impact
on the choice and usage of current and future therapies.
Description of statin-associated
muscle symptoms
SAMS include a wide range of heterogeneous clinical
presentations (myalgia, myopathy and rhabdomyolysis),
reflected by the variety of definitions in the literature and
the absence of a “gold standard” diagnostic test (table 1)
[11]. Symptoms such as muscle pain or aching, stiffness,
tenderness, weakness or cramp (also referred to as my-
algia), possibly associated with statin use, occur mainly
without an elevation of CK and are usually symmetrical
[18, 19]. In addition, the occurrence of subclinical muscle
disturbances (asymptomatic) has been described with the
use of statins in observational studies, but the clinical long-
term consequence remains still unclear [20–22]. The ab-
sence of a dedicated questionnaire in randomised con-
trolled trials and of placebo controls in observational stud-
ies represent methodological limitations that still make it
difficult to determine any causal inference between statin
use and muscle symptoms.
In clinical practice, the temporal association of SAMS with
statin initiation, discontinuation and rechallenge can help
to make a clinical diagnosis. The large majority of patients
who present SAMS are able to tolerate another statin for at
least 12 months after switching, suggesting that the causes
of SAMS may not be only due, or generalisable, to statins
[6]. However, the occurrence of prolonged muscular dam-
age might prevail, limiting the possibility of statin re-ex-
posure. In addition, elderly patients have other comorbid-
ities including osteoarticular disorders that can mimic the
musculoskeletal symptoms observed with statins [23]. Ser-
ious adverse events, such as SAMS associated with CK el-
evations >10-fold, are referred to as myopathy and their
incidence is approximately 1 per 10 000 patients per year
with a standard statin dose (e.g., simvastatin 40 mg daily)
[9]. The risk, however, varies among statins, and increases
with higher statin doses and relative to patient character-
istics (age >80 years, female, low body mass index) [10].
Rhabdomyolysis, occurring in about 1 in 100 000 statin-
treated patients per year, is a severe form of muscle dam-
age associated with very high CK levels, myoglobinaemia
and/or myoglobinuria, and a concomitantly increased risk
of renal failure [9].
Impact of statin-associated muscle
symptoms on current therapy
In 2013, the American Heart Association (AHA) / Amer-
ican College of Cardiology (ACC) recommended tailoring
statin treatment intensity with lower doses in patients at
risk of side effects, such as elderly patients or those taking
drugs that might interact with statins (e.g., patients with hu-
man immunodeficiency virus or immunosuppressant ther-
apies) [2]. In patients taking immunosuppressants, such as
after transplantation, or in patients with chronic kidney dis-
ease, the risk of developing dyslipidaemia is increased, but
the evidence for the benefit of statins is limited, given the
lack of data. SAMS could have a huge impact on the con-
tinuation of therapy, as it remains a frequent reason (up to
75%) for patients or physicians to opt for treatment discon-
tinuation within 2 years of statin therapy initiation [24, 25].
Such nonadherence is associated with poorer clinical out-
comes, as suggested by higher mortality in secondary pre-
vention [26]. However, the discontinuation of statin ther-
apy is a source of concern mostly for the group of patients
at low risk (e.g., primary prevention) or those presenting
a benign condition, such as myalgia without CK elevation.
The fear of side effects, a negative “conviction” or image
of statin therapy among the general population, or even
physicians, can all contribute to statin therapy discontinu-
ation and are probably the most common factors that im-
pact current statin therapy decisions [27]. For most cases a
Table 1: Classification of statin-associated muscle symptoms proposed by the EAS/ESC Consensus Panel [11].
Group Symptoms Biomarker Comment Association with statin
None CK <4 × ULN Raised CK found incidentally May be related to statin therapy, check thyroid
function or if exercise-related.
None CK >4 × ULN Small asymptomatic rises in CK have been
observed.
Clinical significance is unclear.
Muscle symptoms Normal CK Often called “myalgia”. May be related to statin therapy. Causality is
uncertain.
Myalgia
Muscle symptoms CK <10 × ULN Minor elevations of CK in the context of muscle
symptoms are commonly due to increased
exercise or physical activity.
May be statin related or indicate an increased risk
for severe underlying muscle problems.
Myopathy Muscle symptoms CK >10 × ULN Often called “myopathy” by regulatory agencies.
Pain is typically generalised and proximal with
muscle tenderness and weakness.
An excess with usual statin dose about 1 per
10 000 per year. May be associated with
underlying muscle disease.
Rhabdomyolysis Muscle symptoms CK >40 × ULN Rhabdomyolysis when associated with renal
impairment and/or myoglobinuria.
Statin therapy should not be reintroduced.
CK = creatinine kinase; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; ULN = upper limit of normal.
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rechallenge with another statin at a lower dose is well tol-
erated [6]. Given the absence of alternative lipid-lowering
agents with comparable efficacy, the occurrence of SAMS
could be having a major negative impact on the treatment
of hypercholesterolaemia, and thereby on the risk of devel-
oping CVD [11]. In this regard, the physician’s role is es-
pecially important to best manage SAMS and encourage,
where possible, the use of this efficacious and well-docu-
mented therapy for the prevention and treatment of CVD.
Management of statin-associated
muscle symptoms
Recently, the ESC and EAS published a consensus paper
providing guidance on the definition and management of
SAMS [11]. In the event of SAMS, a critical approach is
needed to exclude secondary causes (hypothyroidism and
other common myopathies, such as polymyalgia rheumatic
or intensive physical activity). Patients should be screened
for other agents associated with muscle side effects, drug-
drug interactions or polymedication. After excluding sec-
ondary causes or predisposing factors for SAMS, a careful
assessment of the reason why a statin was prescribed, in-
cluding its risk/benefit ratio, is recommended (fig. 1). Pa-
tients in secondary prevention clearly benefit from statin
therapy and in this case priority should be given to statin
continuation/reinitiation strategies to overcome muscle
symptoms.
All statins have a common mechanism of action, but each
has a specific chemical structure, pharmacokinetic proper-
ties and lipid-lowering efficacy. Atorvastatin, simvastatin
and fluvastatin are relatively lipophilic, whereas pravast-
atin and rosuvastatin are more hydrophilic [28]. Hydro-
philic statins have greater hepatoselectivity with respect
to hydroxymethylglutaryl-coenzyme A (HMG-CoA) re-
ductase, an important property given that the majority of
Figure 1
Clinical management of statin-associated muscle symptoms based
on the EAS/ESC consensus panel guidelines.
CK = creatinine kinase; EAS = European Atherosclerosis Society;
ESC = European Society of Cardiology; LDL-C = low-density
lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin
kexin 9; SAMS = statin-associated muscle symptoms; ULN = upper
limit of normal. Algorithm based on the EAS/ESC consensus
document [11].
cholesterol is produced in the liver [28]. Statins are pre-
dominantly metabolised by the cytochrome P450 (CYP450)
family of enzymes, including the CYP3A4 isoenzyme that
metabolises the greatest number of drugs in humans [29].
Lipophilic drugs are known to be much more susceptible
to oxidative metabolism by the CYP450 system and are
more likely to produce muscle toxicity because of the risk
of interactions with many drugs that inhibit CYP450 [28].
In cases where SAMS are associated with CK levels <4
× ULN, withdrawal followed by one or more rechallenges
can help determine SAMS causality. Rechallenge strategies
include the use of an alternative statin (up to at least three
different types of statin), a statin at a lower dose, or low
doses of rosuvastatin or atorvastatin on alternate days. If
the LDL-C goal is not achieved with the maximum tol-
erated statin dose (despite rechallenge with at least three
types of statin), the addition of ezetimibe or PCSK9 inhib-
itors may be considered.
For SAMS associated with CK >4 × ULN, statin therapy
should be interrupted but rechallenge strategies, as de-
scribed above, should be attempted in high-risk patients
with concomitant monitoring, unless the CK concentration
is >10 × ULN. In this case, statin treatment should be
stopped to prevent any risk of rhabdomyolysis, and renal
damage and secondary causes should be sought. In the ab-
sence of rhabdomyolysis, rechallenge with lower doses of
a potent statin (atorvastatin or rosuvastatin) can be con-
sidered after normalisation of CK. In the event of rhab-
domyolysis, intravenous hydration and urine alkalisation
are recommended, and statin therapy should be stopped.
If the LDL-C goal is not achieved with the maximum tol-
erated statin dosage, the addition of ezetimibe or PCSK9
inhibitors should be considered [15, 17]. Patients who
present SAMS recurrence after the use of at least three dif-
ferent statins should be referred to a specialist. Of note,
red yeast rice (Monascus purpureus) is a fermented product
that has been shown to reduce LDL-C levels by 20% [30].
However, the evidence is poor on the reduction of cardi-
ovascular events and well-designed randomised controlled
trials are needed, especially regarding SAMS, as red yeast
rice has a statin-like effect.
Impact of statin-associated muscle
symptoms on the use of PCSK9
inhibitors
PCSK9 inhibitors have been intensively studied over recent
years in phase III clinical studies showing dramatic de-
creases in LDL-C levels in patients intolerant to statins, or
on top of the maximum tolerated dose of statin [14, 31].
The development of new lipid-lowering therapies was ur-
gently needed for patients at high risk of cardiovascular
events or those with familial hypercholesterolaemia, as
these patients frequently present poorly controlled LDL-C
levels despite treatment, mainly high-intensity statin ther-
apy [32, 33]. The US Food and Drugs Administration
(FDA) and European Medicines Agency (EMA) have ap-
proved the use of PCSK9 inhibitors in the treatment of hy-
percholesterolaemia if target LDL-C levels could not be
reached despite a maximum tolerated statin dose or in the
case of intolerance to statins [34]. This decision was based
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on two trials showing that PCSK9 inhibitors added to max-
imum tolerated statin doses can further decrease LDL-C
by up to 60%; in both trials, the impact of LDL-C reduc-
tion appeared to have a statistical impact on clinical events,
although neither of these trials was designed to measure
this [35, 36]. In advance of large outcome randomised con-
trolled trials, a recent meta-analysis reviewing the effects
of PCSK9 in adults with hypercholesterolaemia reported a
reduction in cardiovascular mortality by 55% (odds ratio
0.45, 95% confidence interval 0.23–0.86, p = 0.015), al-
though currently the number of reported cardiovascular
deaths is small [37]. PCSK9 clinical trials have mainly en-
rolled patients who had poorly controlled LDL-C despite
maximum tolerated statin doses [14]. In Switzerland, the
use of evolocumab (Repatha®) has been recently approved
by the Swiss Agency for Therpeutic Products (Swissmed-
ic), with specific criteria defining the patients who would
need aggressive lipid-lowering therapy. The costs of these
agents will be a critical issue for payers and clinicians, as
well as the need to focus them on high-risk patients with
poor LDL-C control [38]. It is estimated that the number
neede to treat to save one cardiovascular event over 5 years
is 28, with average treatment costs expected to be between
7000 and 8000 Euro/year [38]. As observed with some ex-
pensive emergent agents in the field of oncology, physi-
cians will need to justify the use of PCSK9 inhibitors ac-
cording to the LDL-C levels of their high-risk patients, as
well as documentation of (1) well-conducted statin therapy
of high intensity (e.g., rosuvastatin 10–20 mg or atorvastat-
in 40–80 mg), or (2) the impossibility to prescribe recom-
mended statin therapy due to side effects, especially SAMS
[39]. However, it has been estimated that at least 50% of
patients considered as “statin intolerant” were in fact tol-
erant of lower or intermittent dosing strategies with statin
rechallenge. Therefore, the ESC panel recommended mon-
itoring the true incidence of statin intolerance to detect a
possible risk if overdiagnosis of SAMS.
New guidance for the rational use of
PCSK9 inhibitors
Recently, a joint consensus statement from the EAS and
ESC provided practical guidance for the use of PCSK9 in-
hibitors in very high cardiovascular risk patients, such as
those with atherosclerotic cardiovascular disease, famili-
al hypercholesterolaemia and statin intolerance. This state-
ment takes an initial position to define criteria for consid-
eration of PCSK9 inhibition pointing out the lack of strong
evidence regarding the impact on clinical outcomes and the
uncertainties regarding cost-effectiveness.
The aim of the ESC/EAS consensus statement was to en-
sure appropriate patient pretreatment before consideration
of PCSK9 inhibition (table 2). The proposed algorithms re-
commend identifying very high-risk patients who would
probably benefit from PCSK9 inhibition via an approach
lowering LDL-C by at least 50% (e.g., from >3.6 mmol/l in
secondary prevention or from >5.0 mmol/l in severe famili-
al hypercholesterolaemia) and consequently reducing sig-
nificantly absolute risk, while also taking into account the
costs of these innovative treatments and financial restraints
on healthcare budgets. This document defined very high-
risk patients as those with atherosclerotic cardiovascular
disease (ASCVD), accelerated ASCVD, or famial hyper-
cholesterolaemia without ASCVD, who are likely to have
an absolute risk reduction of more than 2%/year. These es-
timates are, of course, based on limited data and the re-
commendations will need to be updated once the effects
on clinical outcomes are clarified in ongoing clinical trials.
The task force also recognised that in ASCVD patients with
additional high absolute risk, the use of PCSK9 inhibitors
may be considered with lower LDL-C concentrations of
between 2.6 and 3.4 mmol/l on an individual basis and the
clinician’s judgement of the absolute cardiovascular risk.
However, there are several gaps in the current evidence
for the use of PCKS9 monoclonal antibody therapy: (1)
impact on regression versus progression of atherosclerotic
plaque; (2) impact on cardiovascular outcome; (3) long-
term safety, including neurocognitive and immunogenic ef-
fects; (4) lower and upper age limiss for treatment; (5) cost-
effectiveness in patients populations at different levels of
cardiovascular risk (e.g., coronary disease with comorbid-
ities such as moderate to severe chronic kidney disease).
Ezetimibe inhibits intestinal uptake of dietary and biliary
cholesterol and has the effect of lowering LDL-C levels
by 20% in monotherapy or in addition to statin. In the
IMPROVE-IT trial, (Improved Reduction of Outcomes:
Vytorin Efficacy International Trial) the addition of ezetim-
ibe to standard treatment with simvastatin among 18 144
patients after an acute coronary syndrome (ACS) reduced
the occurrence of cardiovascular events after 5 years
(32.7% vs 34.7%, p = 0.016), as well as the LDL-C levels
(1.8 mmol/l vs 1.4 mmol/l) [40]. The findings from the
IMPROVE-IT trial support the use of ezetimibe as a
second-line therapy if LDL-C target levels are not reached
with maximum tolerated statin therapy, and also as a ne-
cessary therapy before the use of PCSK9 inhibitors is con-
Table 2: Very high-risk patient groups for whom PCSK9 inhibitors may be considered, according to the ESC/EAS panel.
Patient group Previous treatment Criteria for consideration of PCSK9 inhibition
ASCVD, diabetes with
target organ damage or
major risk factor (smoking,
FH or marked
hypertension)
Maximum tolerated efficacious statin (atorvastatin or
rosuvastatin) + ezetimibe
• LDL-C >3.6 mmol/l (140 mg/dl).
• Rapid progression of ASCVD within 5 years and LDL-C
>2.6 mmol/l (100 mg/dl).
Severe FH without
ASCCVD
Maximum tolerated efficacious statin (atorvastatin or
rosuvastatin) + ezetimibe
• LDL-C >5.0 mmol/l (200 mg/dl)
• ≥1 additional risk factor indicative of very high risk
(elevated Lp(a), marked hypertension, diabetes and
premature ASCVD) and LDL-C >4.5 mmol/l.
Statin intolerant Ezetimibe • See above.
ASCVD = atherosclerotic cardiovascular disease; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; FH = familial
hypercholesterolaemia; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase kexin subtilisin 9
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sidered. Therefore, a patient at very high risk with poorly
controlled LDL-C can be treated with three different phar-
macological agents (statins, ezetimibe and PCSK9 inhibit-
ors) to reach the recommended LDL-C targets.
Table 3 summarises LDL-C targets according to risk group.
Situation in Switzerland in secondary
prevention
Recent data on patients in Switzerland who presented ACS
suggested that the prevalence of familial hypercholestero-
laemia was high (about 20%), especially in patients with
premature ACS fo whom it was up to 50% [41, 42]. The
achievement of lipid targets was poor, as only one third
of patients with ACS had an LDL-C level <1.8 mmol/l
and even fewer patients with familial hypercholesterolemia
(less than 10%), although 70% were treated with high-in-
tensity statin therapy. Based on the available data, 10–20%
of patients could have an indication for a PCSK9 inhibitor
after a coronary event. Identifying patients with familial
hypercholesterolaemia with the use of a clinical score, such
as the Dutch classification, can help physicians to select the
patients who will need aggressive lipid-lowering therapies
[43].
Conclusion
The occurrence of SAMS can affect adherence to statin
therapy and, consequently, the prognosis of CVD. The
EAS/ESC consensus panel has recently published a con-
sensus paper on the definition and management of SAMS,
as summarised in this review, as well as guidance for the
use of PCSK9 inhibitors in very high-risk patients. Treat-
ment of lipid disorders is entering a new area with the re-
cent approval of evolocumab. PCSK9 inhibitors provide a
novel therapeutic option for patients who present SAMS
and uncontrolled LDL-C levels. More data will be needed
to clarify the impact of new treatment opportunities on ad-
herence and achievement of lipid targets in real life, includ-
ing the eligibility of patients for PCSK9 inhibitors. It will
be very important to identify which patients with SAMS
can really benefit from PCSK9 inhibitors, and in which
cases the switch to another statin may be sufficient to re-
solve SAMS.
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Figures (large format)
Figure 1
Clinical management of statin-associated muscle symptoms based on the EAS/ESC consensus panel guidelines.
CK = creatinine kinase; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; LDL-C = low-density lipoprotein
cholesterol; PCSK9 = proprotein convertase subtilisin kexin 9; SAMS = statin-associated muscle symptoms; ULN = upper limit of normal.
Algorithm based on the EAS/ESC consensus document [11].
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